Streetbeat News

Revenues

GSK

GSK reaffirms its 2024 financial outlook, expecting turnover growth of 7%-9%, core operating profit growth of 11%-13%, and core EPS growth of 10%-12%. The company revises expectations for its segments, with vaccines expected to decrease slightly, specialty medicines to increase significantly, and general medicines to grow moderately.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 8:39 am

TM

Toyota's global sales dropped for the fourth consecutive month in September, with significant declines in the US and China due to recalls and a price war. Despite this, Toyota's electrified vehicle sales increased by 16%.

Portfolio Pulse from Anan Ashraf

October 30, 2024 | 7:20 am

EWQ

France's GDP growth for Q3 has increased to 1.3% year-over-year, up from 1.0% in the previous quarter. This positive economic data could impact ETFs focused on French markets.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 6:52 am

SKFRY

SKF anticipates a mid-single-digit organic sales decline year-over-year for both Q4 and fiscal year 2024. The company also expects a negative currency impact on operating profit and plans significant capital expenditures.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 6:36 am

EWQ

France's GDP for Q3 grew by 0.4% quarter-over-quarter, surpassing the estimated 0.3% and the previous quarter's 0.2% growth.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 6:33 am

EWQ

France's consumer spending for September increased by 0.1%, matching estimates but showing a decline from the revised 0.4% in the previous month.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 6:32 am

SKFRY

SKF reported Q3 adjusted EPS of $0.39, beating the $0.35 estimate, but sales of $2.27B missed the $2.44B estimate. EPS decreased by 7.14% from last year, and sales decreased by 4.61%.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 6:28 am

UBS

UBS anticipates a mid-single-digit decline in Q4 net interest income for Global Wealth Management and a low single-digit drop in Personal & Corporate Banking. The macroeconomic outlook remains uncertain due to geopolitical conflicts and upcoming US elections. Integration-related expenses are expected to be around USD 1.2bn.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 6:19 am

SDZNY

Sandoz has raised its 2024 net sales growth guidance to high-single digits in constant currency, driven by strong biosimilars and generics demand. The company maintains its core EBITDA margin guidance at approximately 20%.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 6:07 am

SDZNY

Sandoz reported a strong third quarter with net sales of $2.6 billion, marking a 12% increase in constant currencies. The growth was driven by a 37% rise in biosimilars and accelerated generics growth in Europe.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 6:06 am